

Supplementary Table 2. Characteristics of patients after 1-year KT

Clinical index	Non-DM 1	Non-DM 2	Non-DM 3	Non-DM 4	DM 1	DM 2	DM 3	DM 4
Immunosuppressive agents								
Steroid	0	0	0	0	0	0	0	0
Tac	0	0	0	0	0	0	0	0
MMF	0	0	0	0	0	0	0	0
FBS (mg/dL)	88	90	88	96	144	148	111	198
HbA1c (%)	4.1	4.5	5.4	6.0	7.4	5.9	5.9	7.8
Scr (mg/dL)	1.29	1.38	0.77	1.85	0.79	1.36	1.45	1.02
MDRD eGFR (mL/min/1.73 m ²)	58.48	52.04	81.82	41.55	64.69	39.93	48.69	72.84
Tac trough level (ng/mL)	10.0	6.1	6.9	4.1	10.4	5.6	6.8	8.4
Tac dose (mg)	1.5 mg bid	2 mg bid	2 mg bid	3 mg bid	1.5 mg bid	1.5 mg bid	1.5 mg bid	2 mg bid
Mean Tac trough level (ng/mL)	7.28	6.91	7.58	5.12	8.24	8.13	7.64	7.25
CDR (ng/dL/mg/day)	2.43	1.73	1.90	0.85	2.75	2.71	2.55	1.81
Anti-diabetic medication	X	X	X	X	Gliclazide 60 mg qd, linagliptin/metformin 2.5/850 mg bid	Gliclazide 30 mg qd, linagliptin 5 mg qd	Linagliptin/metformin 2.5/500 mg qd	Linagliptin/metformin 2.5/500 mg bid
Acute rejection	0	X	X	0	0	X	X	X
Steroid pulse	0	X	X	0	0	X	X	X
Graft failure	X	X	X	X	X	X	X	X

bid, bis in die; CDR, concentration to dose ratio; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FBS, fasting blood sugar; HbA1c, glycosylated hemoglobin; KT, kidney transplantation; MDRD, modification of diet in renal disease; MMF, mycophenolate mofetil; qd, quaque die; Tac, tacrolimus; Scr, serum creatinine.